Form 8-K - Current report:
SEC Accession No. 0001517022-25-000010
Filing Date
2025-02-07
Accepted
2025-02-07 08:16:59
Documents
14
Period of Report
2025-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K akba-20250203.htm   iXBRL 8-K 33197
  Complete submission text file 0001517022-25-000010.txt   173094

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20250203.xsd EX-101.SCH 2139
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20250203_def.xml EX-101.DEF 3738
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20250203_lab.xml EX-101.LAB 25083
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20250203_pre.xml EX-101.PRE 14595
16 EXTRACTED XBRL INSTANCE DOCUMENT akba-20250203_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 25599371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)